{
  "nctId": "NCT03212521",
  "briefTitle": "Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1",
  "officialTitle": "A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotypes 1 - 6 Infection and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤ 1",
  "protocolDocument": {
    "nctId": "NCT03212521",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2017-07-31",
    "uploadDate": "2019-08-05T14:55",
    "size": 2241754,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03212521/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE3"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 230,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2017-08-07",
    "completionDate": "2018-08-13",
    "primaryCompletionDate": "2018-08-13",
    "firstSubmitDate": "2017-07-07",
    "firstPostDate": "2017-07-11"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Hepatitis C virus (HCV) genotype (GT) 1, 2, 3, 4, 5, or 6 infection. Mixed GT and indeterminate GT may be acceptable.\n* Aspartate aminotransferase (AST) to platelet ratio index (APRI) score of less than or equal to 1, at time of screening.\n* Does not have current active hepatitis B virus infection defined as:\n\n  * positive hepatitis B surface antigen (HBsAg), OR\n  * hepatitis B virus (HBV) deoxyribonucleic acid (DNA) \\> lower limit of quantification (LLOQ) in subjects with isolated positive anti-hepatitis B core (HBc) (i.e., negative HBsAg and anti-hepatitis B surface\\[HBs\\])\n* Platelets ≥ 150,000 cells/mm³\n* Albumin ≥ lower limit of normal (LLN)\n* Positive anti-HCV antibody (Ab) AND plasma HCV ribonucleic acid (RNA) viral load ≥ 1,000 IU/mL at Screening and for at least 6 months before Screening.\n* No past history/evidence of cirrhosis.\n* No history of hepatocellular carcinoma.\n* Hepatitis C virus treatment-naïve (had not received a single dose of any approved or investigational anti-HCV medication).\n* If female, the subject must not be pregnant, breastfeeding, or considering becoming pregnant during the study and for 30 days after the last dose of study drug.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Percentage of Participants in the Modified Intention-to-Treat Population With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)",
        "description": "SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification (LLOQ; 15 IU/mL) 12 weeks after the last dose of study drug.\n\nThe 95% confidence interval (95%CI) was calculated using the Wilson's score method.\n\nEfficacy was to be established if the lower bound of the 95%CI was greater than the threshold of 92.4%, based on the historical rate observed in glecaprevir/pibrentasvir registrational studies in treatment-naïve, non-cirrhotic patients (98.4%) minus a margin of 6%.",
        "timeFrame": "12 weeks after the last actual dose of study drug, Week 20"
      }
    ],
    "secondary": [
      {
        "measure": "Percentage of Participants in the Intention-to-Treat Population With SVR12",
        "description": "SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the LLOQ (15 IU/mL) 12 weeks after the last dose of study drug.\n\nThe 95% confidence interval was calculated using the normal approximation to the binomial distribution. Efficacy was to be established if the lower bound of the 95%CI was greater than the threshold of 91.4%, based on the mITT threshold minus an expected 1% rate of non-virological SVR failures.",
        "timeFrame": "12 weeks after the last actual dose of study drug, Week 20"
      },
      {
        "measure": "Percentage of Participants With On-treatment Virologic Failure",
        "description": "On-treatment virologic failure was defined as one of the following conditions:\n\n* confirmed HCV RNA ≥ 100 IU/mL after HCV RNA \\< 15 IU/mL during the Treatment Period; or\n* confirmed increase from nadir in HCV RNA (two consecutive HCV RNA measurements \\> 1 log₁₀ IU/mL above nadir) at any time point during the Treatment Period; or\n* HCV RNA ≥ 15 IU/mL at end of treatment with at least 6 weeks of treatment, where the HCV RNA value must be collected on or after Study Drug Day 36 and study drug duration ≥ 36 days.",
        "timeFrame": "Up to 8 weeks"
      },
      {
        "measure": "Percentage of Participants With Post-treatment Relapse",
        "description": "Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA levels \\< LLOQ at the end of treatment.",
        "timeFrame": "From the end of treatment (Week 8) through 12 weeks after the last dose of study drug (Week 20)"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 0,
      "exclusionCount": 0,
      "totalCount": 0
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 3,
      "otherCount": 0,
      "totalCount": 4
    },
    "studyDesign": {
      "phases": [
        "PHASE3"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 25,
    "complexityCategory": "Simple"
  },
  "collectionDate": "2025-09-22T02:30:23.633Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}